Similar Items: Outcome Measures for Dementia in the Advanced Stage and at the End of Life
- Six‐month real‐world amyloid PET outcomes after lecanemab: Greater amyloid reduction at the MCI stage than in dementia
- Advances in pharmacotherapy for vascular cognitive impairment and vascular dementia: An update of 2025
- Mid‐ and late‐life depression increases risk of Alzheimer's disease and related dementias in veterans
- Use of Wearable Technology for Measuring and Characterizing Sedentary Behavior in People With Mild Cognitive Impairment and Dementia: Systematic Review
- Pharmacogenetic analyses in people with dementia in Northeast Germany
- Frontotemporal dementia in Hispanic populations: Regional and national comparisons